Filing Flows › Biofrontera (BFRI) › Q1 2025
Biofrontera (BFRI) Q1 2025 earnings results (first quarter 2025)
10-Q filed May 15, 2025
Biofrontera (BFRI) reported revenue of $8.6M for the first quarter 2025 (Q1 2025), +9% from a year earlier and -32% from the quarter before. Operating margin was -52.9%, net loss $4.2M (48.9% of revenue).
Biofrontera, Q1 2025: revenue $8.6M (+8% year over year), operating margin -52.9%, net loss $4.2M, operating cash flow −$4.1M. The chart follows the revenue to costs, profit and cash.
| Q1 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $8.6M | -32% | +9% |
| Operating profit | −$4.5M | — | — |
| Net earnings | −$4.2M | — | — |
| Operating cash flow | −$4.1M | — | — |
What changed
Revenue was $8.6M in Q1 2025, up 9% year over year and down 32% from the previous quarter.
Operating costs exceeded revenue by $4.5M, an operating margin of -52.9%. Total costs fell 2% while revenue rose 9%. The fastest-growing cost line was Research & development (+7000%). The quarter ended with a net loss of $4.2M, wider than the previous quarter's $1.4M loss.
Operating cash flow was −$4.1M. Non-cash charges added back $29K of depreciation and amortization and $239K of share-based compensation. Capital expenditures of $3K exceeded it, leaving free cash flow of −$4.1M.
Questions
What was Biofrontera's revenue in the first quarter 2025?
Biofrontera (BFRI) reported revenue of $8.6M for the first quarter 2025 (Q1 2025), +9% from a year earlier and -32% from the quarter before.
Was Biofrontera profitable in the first quarter 2025?
Operating loss was $4.5M (-52.9% of revenue) and net loss $4.2M.
Source: Biofrontera 10-Q on SEC EDGAR.